In September 2024, we hosted our hybrid DTRF International Desmoid Tumor Research Workshop in conjunction with the DTRF Together We Will Weekend in Houston, TX. Scroll down the agenda to watch the video recordings from the workshop.
Agenda
“Cellular heterogeneity.”
Ben Alman, MD
Department Chair, Orthopedic Surgery
“Efficacy and safety of auranofin for progressive desmoid-type fibromatosis: an open-label phase II trial.”
Yoshihiro Nishida, MD
Department of Rehabilitation Medicine, Orthopaedic Surgery
"Multiomic profiling uncovers integral immune molecules that drive the pathogenic fibroblast milieu in desmoid tumors."
Cristabelle De Souza, PhD
Instructor
“Impact of Pain on Physical and Role Functioning in Adult Patients with Desmoid Tumors Treated with Nirogacestat.”
Ravin Ratan, MD
Medical Oncologist
“Impact of nirogacestat on patient-reported outcomes in adults with desmoid tumor with a best overall response of stable disease: post hoc analysis from the DeFi study.” (Encore of ESMO Sarcoma 2024 mini-oral presentation)
Ravin Ratan, MD
Medical Oncologist
"Therapeutic targeting of the hexosamine biosynthesis pathway in desmoid tumors."
Joanna Przybyl, PhD and Richard Miallot, PhD
“DTRF Natural History Study Updates.”
Amanda Lucas
Registry Administrator, The DTRF Patient Registry & Natural History Study
"The Role of Surgery in FAP associated Desmoid Disease: From Prevention to Intestinal Transplant."
David Liska, MD, MA, FACS, FASCRS
Chair, Department of Colorectal Surgery
“To see the early effect of sorafenib on cognition, cardiovascular and reproductive functions in patients with fibromatosis.”
Sameer Rastogi, MD
Additional Professor, Medical Oncology
“Trans-arterial Doxorubicin Eluting Embolotherapy for Desmoids: a prospective, multicenter study design.”
Eldad Elnekave, MD
Interventional Radiologist
“Magnetic resonance image-guided high intensity focused ultrasound for patients with desmoid-type fibromatosis: the MAGNIFIED trial."
Stefanie Hakkesteegt, MD
PhD candidate
